US 7,579,362 B2
Aza-bicycloalkyl ethers and their use as alpha7-nAChR agonists
Dominik Feuerbach, Mullheim (Germany); Konstanze Hurth, Saint Louis (France); and Timothy J Ritchie, London (United Kingdom)
Assigned to Novartis AG, Basel (Switzerland)
Filed on Jun. 26, 2007, as Appl. No. 11/823,312.
Application 11/823312 is a continuation of application No. 10/526759, abandoned, previously published as PCT/EP03/09772, filed on Sep. 03, 2003.
Claims priority of application No. 0220581.3 (GB), filed on Sep. 04, 2002.
Prior Publication US 2007/0249617 A1, Oct. 25, 2007
Int. Cl. A61K 31/4418 (2006.01); A61K 31/439 (2006.01); C07D 453/02 (2006.01); C07D 487/08 (2006.01); A61K 31/4412 (2006.01); C07D 401/14 (2006.01); A61P 25/00 (2006.01); A61K 31/4545 (2006.01); A61K 31/506 (2006.01); A61K 31/501 (2006.01)
U.S. Cl. 514—305  [546/137; 546/183; 546/276.7; 544/238; 544/315; 514/339] 13 Claims
 
1. The compound of formula I

OG Complex Work Unit Drawing
wherein
X is CH2 or a single bond;
Y is a group of formula

OG Complex Work Unit Drawing
and
R is phenyl, naphthyl, tetrahydronaphthyl, indanyl, thienyl, benzothienyl, furanyl, benzofuranyl and isobenzofuranyl, which in each case can be unsubstituted or mono-, di- or trisubstituted by halogen, cyano, formyl, acetyl, C1-C3alkoxycarbonyl, N,N-di-(C1-C3alkyl) carbamoyl, phenyl, phenoxy, methylendioxy, ethylendioxy; or
C1-C4alkyl, C2-C4alkenyl, C2-C4alkinyl or C1-C4alkoxy, which radicals themselves can be unsubstituted or mono-, di- or trisubstituted by halogen;
in free base or acid addition salt form.